Remove 2004 Remove Communication Remove Dosage
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS Pharmaceutical Strategy for Europe. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. This obviously presents a huge magnitude of risk for drug developers,” he noted.

article thumbnail

Medicare Part D for LTC Pharmacy: A Refresher

Integra X Files

Industry representatives spent many hours during 2004 discussing the needs of nursing home residents and the current standards of service. Keep communicating with your facility customers to understand how enrollment is changing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Celebrating Pharmacists – The Path and Fun Facts

Community Pharmacy

Since 2004, October has been highlighted as American Pharmacist Month , a time to recognize and celebrate the profession of pharmacy. Combining the cutting edge of medical science and chemistry, pharmacists for centuries have played a key role in local communities.

article thumbnail

Root Causes of Depression and Hashimoto’s

The Thyroid Pharmacist

It breaks my heart to think about the many thyroid patients who get labeled as clinically depressed instead of being tested for thyroid antibodies, and to think of the patients who start on thyroid hormones without consideration of dosage and form, resulting in ongoing symptoms, including depression. Published 2004 Aug 18.

Dosage 122
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.